{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:53:45Z","timestamp":1792479225508,"version":"4.5.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>This study assessed prostate cancer burden and trends in major BRICS countries (Brazil, Russia, India, China, and South Africa) from 1990 to 2019.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Utilizing Global Burden of Disease Study 2019 data, we calculated age-standardized rates for prostate cancer incidence, prevalence, mortality, and disability-adjusted life years (DALYs) with 95% uncertainty intervals (UIs). Joinpoint regression analysis determined the average annual percentage change (AAPC) for trend characterization.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Prostate cancer ranked highest in China for incidence, prevalence, mortality, and DALYs. In 2019, Brazil had the highest age-standardized incidence rate (ASIR) [55.029 (95% UI: 47.744\u201381.831)] and age-standardized prevalence rate (ASPR) [372.511 (95% UI: 327.549\u2013549.128)], while South Africa recorded the highest age-standardized mortality rate (ASMR) [42.241 (95% UI: 32.146\u201347.933)], and age-standardized DALY rate (ASDR) [666.085 (95% UI: 522.626\u2013764.612)]. ASIR and ASPR increased significantly over three decades (AAPC\u2005&gt;\u20050), with varying ASMR and ASDR trends.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Prostate cancer poses a significant public health challenge. While incidence and prevalence rise, mortality declines in China, India, and Brazil. Tailored health policies are crucial to address diverse disease burden characteristics.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cej.0000000000000890","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T08:07:27Z","timestamp":1712736447000},"page":"83-88","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Prostate cancer burden in major BRICS countries, 1990\u20132019: findings from the 2019 global burden of disease study"],"prefix":"10.1097","volume":"34","author":[{"given":"Juan","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Urology, Shengli Oilfield Central Hospital, Dongying, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Urology, Shengli Oilfield Central Hospital, Dongying, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuting","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Shengli Oilfield Central Hospital, Dongying, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Urology, Shengli Oilfield Central Hospital, Dongying, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"key":"R1-20241205","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2471\/BLT.14.140889","article-title":"BRICS and global health.","volume":"92","author":"Acharya","year":"2014","journal-title":"Bull World Health Organ"},{"key":"R2-20241205","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.juro.2009.08.104","article-title":"Growth inhibitory effect of low fat diet on prostate cancer cells: results of a prospective, randomized dietary intervention trial in men with prostate cancer.","volume":"183","author":"Aronson","year":"2010","journal-title":"J Urol"},{"key":"R3-20241205","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R4-20241205","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent global patterns in prostate cancer incidence and mortality rates.","volume":"77","author":"Culp","year":"2020","journal-title":"Eur Urol"},{"key":"R5-20241205","doi-asserted-by":"crossref","first-page":"e484","DOI":"10.1016\/S1470-2045(14)70211-6","article-title":"Prevention and early detection of prostate cancer.","volume":"15","author":"Cuzick","year":"2014","journal-title":"Lancet Oncol"},{"key":"R6-20241205","doi-asserted-by":"crossref","first-page":"365","DOI":"10.15171\/ijhpm.2014.118","article-title":"Essential drugs production in Brazil, Russia, India, China and South Africa (BRICS): opportunities and challenges.","volume":"3","author":"Ezziane","year":"2014","journal-title":"Int J Health Policy Manag"},{"key":"R7-20241205","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/jcmm.12055","article-title":"Toll-like receptors in prostate infection and cancer between bench and bedside.","volume":"17","author":"Gambara","year":"2013","journal-title":"J Cell Mol Med"},{"key":"R8-20241205","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019.","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"R9-20241205","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2018.3710","article-title":"Screening for prostate cancer: US preventive services task force recommendation statement.","volume":"319","author":"Grossman","year":"2018","journal-title":"JAMA"},{"key":"R10-20241205","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0022-5347(05)65382-7","article-title":"Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data.","volume":"167","author":"Hock","year":"2002","journal-title":"J Urol"},{"key":"R11-20241205","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/S1470-2045(18)30447-9","article-title":"The burden of cancers and their variations across the states of India: the Global Burden of Disease Study 1990","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"key":"R12-20241205","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.mgene.2014.07.007","article-title":"Epidemiology of prostate cancer in India.","volume":"2","author":"Jain","year":"2014","journal-title":"Meta Gene"},{"key":"R13-20241205","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/bju.16178","article-title":"Global viewpoints: updates on prostate cancer in sub-Saharan Africa.","volume":"133","author":"Jalloh","year":"2024","journal-title":"BJU International"},{"key":"R14-20241205","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1590\/0102-311X00007314","article-title":"Future burden of prostate cancer mortality in Brazil: a population-based study.","volume":"30","author":"Jerez-Roig","year":"2014","journal-title":"Cad Saude Publica"},{"key":"R15-20241205","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.3390\/ijerph17114139","article-title":"Physical rehabilitation needs in the BRICS nations from 1990 to 2017: cross-national analyses using data from the Global Burden of Disease Study.","volume":"17","author":"Jesus","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"R16-20241205","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1158\/1055-9965.EPI-23-1034","article-title":"Trends of prostate cancer morbidity in low-incidence countries from 1990","volume":"33","author":"Jiang","year":"2024","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R17-20241205","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jamaoncol.2021.6987","article-title":"Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019.","volume":"8","author":"Kocarnik","year":"2022","journal-title":"JAMA Oncol"},{"key":"R18-20241205","doi-asserted-by":"crossref","first-page":"155","DOI":"10.5213\/inj.2014.18.3.155","article-title":"The study about physical activity for subjects with prevention of benign prostate hyperplasia.","volume":"18","author":"Lee","year":"2014","journal-title":"Int Neurourol J"},{"key":"R19-20241205","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00345-019-02872-x","article-title":"Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations.","volume":"38","author":"Mukherji","year":"2020","journal-title":"World J Urol"},{"key":"R20-20241205","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.juro.2017.10.044","article-title":"Global, regional and national burden of prostate cancer, 1990 to 2015: results from the Global Burden of Disease Study 2015.","volume":"199","author":"Pishgar","year":"2018","journal-title":"J Urol"},{"key":"R21-20241205","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.juro.2017.10.044","article-title":"Global, regional and national burden of prostate cancer, 1990 to 2015: results from the Global Burden of Disease Study 2015.","volume":"199","author":"Pishgar","year":"2018","journal-title":"J Urol"},{"key":"R22-20241205","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/pcan.2015.54","article-title":"Racial differences in the relationship between clinical prostatitis, presence of inflammation in benign prostate and subsequent risk of prostate cancer.","volume":"19","author":"Rybicki","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R23-20241205","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s13167-019-00169-y","article-title":"The burden of prostate cancer is associated with human development index: evidence from 87 countries, 1990","volume":"10","author":"Sharma","year":"2019","journal-title":"EPMA J"},{"key":"R24-20241205","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R25-20241205","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics.","volume":"65","author":"Torre","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"R26-20241205","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1172\/JCI80006","article-title":"Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages.","volume":"125","author":"Ugel","year":"2015","journal-title":"J Clin Invest"},{"key":"R27-20241205","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nrurol.2010.102","article-title":"Diet and prostate cancer: mechanisms of action and implications for chemoprevention.","volume":"7","author":"Venkateswaran","year":"2010","journal-title":"Nat Rev Urol"},{"key":"R28-20241205","doi-asserted-by":"crossref","first-page":"853623","DOI":"10.3389\/fendo.2022.853623","article-title":"Burden of prostate cancer in China, 1990","volume":"13","author":"Wang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R29-20241205","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/cncr.32733","article-title":"Incidence and disease burden of prostate cancer from 1990 to 2017: results from the Global Burden of Disease Study 2017.","volume":"126","author":"Zhai","year":"2020","journal-title":"Cancer"}],"container-title":["European Journal of Cancer Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000890","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T10:01:19Z","timestamp":1733392879000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cej.0000000000000890","relation":{},"ISSN":["0959-8278","1473-5709"],"issn-type":[{"value":"0959-8278","type":"print"},{"value":"1473-5709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,9]]}}}